Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6

According to data from the phase 2 EPCORE NHL-6 study—presented during the 2024 ASCO Annual Meeting—patients with relapsed/refractory DLBCL and follicular lymphoma were successfully treated with subcutaneous epcoritamab in the outpatient setting. CRS incidence and severity were comparable to that reported in the EPCORE NHL-1 trial and were appropriately managed in this outpatient setting.